Skip to main content

Safety and clinical activity of atezolizumab (atezo) + radium-223 dichloride (r-223) in 2L metastatic castration-resistant prostate cancer (mCRPC): Results from a phase Ib clinical trial.

Publication ,  Conference
Morris, MJ; Fong, L; Petrylak, DP; Sartor, AO; Higano, CS; Pagliaro, LC; Alva, AS; Appleman, LJ; Tan, W; Vaishampayan, UN; Porcu, R; Tayama, D ...
Published in: JOURNAL OF CLINICAL ONCOLOGY
2020

Duke Scholars

Published In

JOURNAL OF CLINICAL ONCOLOGY

EISSN

1527-7755

ISSN

0732-183X

Publication Date

2020

Volume

38

Issue

15

Related Subject Headings

  • Oncology & Carcinogenesis
  • 3211 Oncology and carcinogenesis
  • 1112 Oncology and Carcinogenesis
  • 1103 Clinical Sciences
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Morris, M. J., Fong, L., Petrylak, D. P., Sartor, A. O., Higano, C. S., Pagliaro, L. C., … Armstrong, A. J. (2020). Safety and clinical activity of atezolizumab (atezo) + radium-223 dichloride (r-223) in 2L metastatic castration-resistant prostate cancer (mCRPC): Results from a phase Ib clinical trial. In JOURNAL OF CLINICAL ONCOLOGY (Vol. 38).
Morris, Michael J., Lawrence Fong, Daniel Peter Petrylak, A Oliver Sartor, Celestia S. Higano, Lance C. Pagliaro, Ajjai Shivaram Alva, et al. “Safety and clinical activity of atezolizumab (atezo) + radium-223 dichloride (r-223) in 2L metastatic castration-resistant prostate cancer (mCRPC): Results from a phase Ib clinical trial.” In JOURNAL OF CLINICAL ONCOLOGY, Vol. 38, 2020.
Morris MJ, Fong L, Petrylak DP, Sartor AO, Higano CS, Pagliaro LC, Alva AS, Appleman LJ, Tan W, Vaishampayan UN, Porcu R, Tayama D, Kadel EE, Yuen KCY, Datye A, Armstrong AJ. Safety and clinical activity of atezolizumab (atezo) + radium-223 dichloride (r-223) in 2L metastatic castration-resistant prostate cancer (mCRPC): Results from a phase Ib clinical trial. JOURNAL OF CLINICAL ONCOLOGY. 2020.

Published In

JOURNAL OF CLINICAL ONCOLOGY

EISSN

1527-7755

ISSN

0732-183X

Publication Date

2020

Volume

38

Issue

15

Related Subject Headings

  • Oncology & Carcinogenesis
  • 3211 Oncology and carcinogenesis
  • 1112 Oncology and Carcinogenesis
  • 1103 Clinical Sciences